Join Now

Utah Life Sciences News & Events

American Diabetes Association and Renalytix Partner to Prioritize Kidney Health in Type 2 Diabetes Population

January 5, 2022

The American Diabetes Association® (ADA) and Renalytix announced a joint program to improve overall kidney health in patients with type 2 diabetes (T2D) in the United States, which is expected to grow from 34 million individuals today to nearly 60 million by 20601. The program intends to drive early detection and risk-informed care delivery to delay disease progression, reduce dialysis starts and improve overall health of chronic kidney disease (CKD) patients with diabetes nationally.

“Early identification and risk-informed care are critical to better health outcomes,” said Dr. Nuha El Sayed, Vice President of Healthcare Improvement at the American Diabetes Association. “Our work together will support the care of people with diabetes through primary care providers.”

Together, ADA and Renalytix will convene experts to advise and develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction. The ADA and Renalytix will work together to define a plan for a second phase of the program to scale and deploy the model through partnerships with multiple health systems nationally. That effort will leverage milestones, KPIs, metrics and ongoing evaluation of the Pathway’s effectiveness in changing outcomes for people with diabetes living with or at-risk for CKD.

“This program combines technology, hospital system population health engagement and leading clinical experts to drive optimized care management at the earliest possible stage of kidney disease where better outcomes and cost control can be maximized,” said James McCullough, CEO of Renalytix. “For individuals with diabetes and kidney disease, this is a powerful, comprehensive and bold model to engage this devastating disease beginning in primary care and close the gaps in front-line care.”

The number of adults with diagnosed diabetes is expected to reach 60 million by 2060 in the United States alone, with up to 40 percent expected to develop chronic kidney disease. Chronic kidney disease is a silent disease, that each year kills more people than breast and prostate cancer alone.



1 https://pubmed.ncbi.nlm.nih.gov/29903012/
2 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
3 https://www.nicresearch.com/clinical-research-necessary-nephrology/
4 https://optn.transplant.hrsa.gov/
5 https://www.cdc.gov/diabetes/basics/type2.html
6 https://www.cdc.gov/kidneydisease/publications-resources/link-between-ckd-diabetes-heart-disease.html


Media Contacts:
United States:
Chloe Beaudoin
(207) 333-7947

Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303